1247001-61-1 Usage
Description
(S)-1-(1-benzyl-1H-indazol-6-yl)ethane-1,2-diol is a compound belonging to the indazole derivatives family. It features a benzyl group attached to an indazole ring, which is connected to a diol moiety. This unique chemical structure endows it with potential applications in medicinal chemistry, particularly in the development of novel drugs. The presence of the diol group suggests the possibility of interactions with biological systems, while the benzyl and indazole groups offer opportunities for specific molecular interactions with biological targets. The stereochemistry at the chiral center indicates the existence of this compound as a single enantiomer, which may influence its biological activity. These characteristics make (S)-1-(1-benzyl-1H-indazol-6-yl)ethane-1,2-diol a promising candidate for further exploration in drug discovery and development.
Uses
Used in Pharmaceutical Industry:
(S)-1-(1-benzyl-1H-indazol-6-yl)ethane-1,2-diol is used as a potential drug candidate for its unique chemical structure that allows for specific molecular interactions with biological targets. The presence of the diol group and the benzyl and indazole groups enables it to potentially interact with biological systems, making it a valuable compound for the development of new medications.
Used in Drug Discovery and Development:
(S)-1-(1-benzyl-1H-indazol-6-yl)ethane-1,2-diol is utilized as a subject of interest in drug discovery and development due to its potential for specific molecular interactions and the implications of its single enantiomer existence on biological activity. (S)-1-(1-benzyl-1H-indazol-6-yl)ethane-1,2-diol's unique structure and properties make it a valuable asset for the creation of innovative therapeutics.
Check Digit Verification of cas no
The CAS Registry Mumber 1247001-61-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,7,0,0 and 1 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1247001-61:
(9*1)+(8*2)+(7*4)+(6*7)+(5*0)+(4*0)+(3*1)+(2*6)+(1*1)=111
111 % 10 = 1
So 1247001-61-1 is a valid CAS Registry Number.
1247001-61-1Relevant articles and documents
The discovery of polo-like kinase 4 inhibitors: Identification of (1 R,2 S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1 H -indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a potent, orally active antitumor agent
Sampson, Peter B.,Liu, Yong,Forrest, Bryan,Cumming, Graham,Li, Sze-Wan,Patel, Narendra Kumar,Edwards, Louise,Laufer, Radoslaw,Feher, Miklos,Ban, Fuqiang,Awrey, Donald E.,Mao, Guodong,Plotnikova, Olga,Hodgson, Richard,Beletskaya, Irina,Mason, Jacqueline M.,Luo, Xunyi,Nadeem, Vincent,Wei, Xin,Kiarash, Reza,Madeira, Brian,Huang, Ping,Mak, Tak W.,Pan, Guohua,Pauls, Henry W.
, p. 147 - 169 (2015/03/03)
Previous publications from our laboratory have introduced novel inhibitors of Polo-like kinase 4 (PLK4), a mitotic kinase identified as a potential target for cancer therapy. The search for potent and selective PLK4 inhibitors yielded (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which were superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-ones, e.g., 3. The later scaffold confers improved drug-like properties and incorporates two stereogenic centers. This work reports the discovery of a novel one-pot double SN2 displacement reaction for the stereoselective installation of the desired asymmetric centers and confirms the stereochemistry of the most potent stereoisomer, e.g., 44. Subsequent work keys on the optimization of the oral exposure of nanomolar PLK4 inhibitors with potent cancer cell growth inhibitory activity. A short list of compounds with superior potency and pharmacokinetic properties in rodents and dogs was studied in mouse models of tumor growth. We conclude with the identification of compound 48 (designated CFI-400945) as a novel clinical candidate for cancer therapy.
